The membrane-distal region (MDR), which binds to MUC16, is represented by region I. The MSLN MDR has emerged as the primary target for current immunotherapy approaches because of the role the MSLN–MUC16 relationship plays in tumor development [41]. This evidence concerns the gene MSLN and neoplasm.